RecruitingPhase 2NCT07040566
A Trial of Varenicline for E-cigarette Cessation
Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults
Sponsor
Yale University
Enrollment
326 participants
Start Date
Oct 14, 2025
Study Type
INTERVENTIONAL
Summary
This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- report daily use of an e-cigarette containing nicotine
- live in Connecticut or South Carolina
Exclusion Criteria4
- regular use of other tobacco products besides e-cigarettes
- medical contraindications for varenicline use
- current treatment for tobacco cessation
- lack proficiency in English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVarenicline 1mg BID
12 weeks following the standard titration of 1 mg, twice daily
DRUGPlacebo
Matching placebo twice daily
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07040566